On May 12, 2025, Royalty Pharma plc held its Annual General and Special Meeting of Shareholders, where 15 proposals were voted on. Shareholders approved the Membership Interest Purchase Agreement, the 2025 Equity Incentive Plan, and authorized share repurchases. All nine director nominees were elected. Non-binding votes approved compensation for named executive officers and the UK remuneration reports. Ernst & Young was reappointed as both the U.S. and UK statutory auditor. The board was authorized to allot shares, including without pre-emption rights. All proposals received majority support.